Clinical response and improvements in health‐related quality of life in patients with moderate‐to‐severe psoriasis treated with guselkumab over 5 years: results from VOYAGE 1 and VOYAGE 2

2021 ◽  
Vol 185 (6) ◽  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Severe Psoriasis ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

Dermatology ◽  
2008 ◽  
Vol 216 (3) ◽  
pp. 260-270 ◽  
Author(s):  
Dennis A. Revicki ◽  
Mary K. Willian ◽  
Alan Menter ◽  
Jean-Hilaire Saurat ◽  
Neesha Harnam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Plaque Psoriasis ◽  
Response To Therapy ◽  
Health Related Quality ◽  
Life Outcomes ◽  
Severe Plaque Psoriasis ◽  
Related Quality ◽  
Health Related

The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4558-4558 ◽  
Author(s):  
L. Kvols ◽  
J. E. Glusman ◽  
E. A. Hahn ◽  
E. Wang ◽  
K. Öberg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Response ◽  
Functional Assessment ◽  
Well Being ◽  
Health Related Quality ◽  
Metastatic Carcinoid ◽  
Octreotide Lar ◽  
Related Quality ◽  
Health Related

4558 Background: Pasireotide is a novel multi-ligand somatostatin analogue with high affinity binding for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5). This Phase II clinical trial showed that pasireotide is effective in controlling the symptoms of diarrhea and flushing in 27% of patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. The impact of pasireotide therapy on health-related quality of life (HRQL) was also evaluated. Methods: Patients in this open-label, multicenter study initially received pasireotide 300 μg sc bid which was escalated to a maximum dose of 1,200 μg sc bid until clinical response was achieved. Data are reported for the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) instrument. FACIT-D comprises the Functional Assessment of Cancer Therapy-General (FACT-G) score, which measures physical, social, emotional and functional well-being, plus a symptom-specific sub-scale which measures HRQL specific to diarrhea. FACIT-D baseline assessment was obtained on day 1 immediately before dosing, and then monthly thereafter. FACIT-D sub-scale and total scores at baseline and after 1, 2, and 3 months of pasireotide treatment are described by categories of clinical response. Results: 45 patients (mean age 61 years; range 40–83) received treatment, and 44 were eligible for the efficacy and HRQL analyses. Functional well-being scores, symptom-specific scores and total FACIT-D scores of non-responders tended to be lower at baseline and during treatment than those of responders. The three sub-scale and summary FACIT-D scores exhibited relatively stable mean HRQL scores and similar patterns of variability in clinical responders and non- responders through the third month of pasireotide treatment. Conclusions: HRQL was stable during treatment with pasireotide in patients with advanced metastatic disease refractory or resistant to octreotide LAR. Additional work in HRQL study design and evaluation of HRQL endpoints in patients with carcinoid disease is indicated, and will further improve our understanding of quality of life in patients with this disease. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document